Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Vernant

Showing results (281-290 of 307) with videos related to

Pageof 31
Sort By:
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Lancet (London, England)|May 3, 2000
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow TransplantationF Frassoni, M Labopin, R Powles, et al.
Leukemia|January 20, 2009
Fully functional NK cells after unrelated cord blood transplantationV Beziat, S Nguyen, S Lapusan, et al.
Leukemia & Lymphoma|March 23, 2002
Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remissionA Delannoy, B Cazin, X Thomas, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
British Journal of Haematology|June 1, 1997
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM)G Socié, J Y Cahn, J Carmelo, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|May 7, 2017
[Not-for-profit: A report from the fourth annual symposium of ethics held by the National Institute for Blood Transfusion (France)]J Ceccaldi, J-B Thibert, A Haddad, et al.
British Journal of Haematology|February 14, 2002
Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemiaA Pigneux, M L Tanguy, M Michallet, et al.
Blood|June 8, 2001
Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remissionD Blaise, D Maraninchi, M Michallet, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow TransplantationY Belkacemi, M Labopin, J P Vernant, et al.
Pageof 31

Showing results (281-290 of 307) with videos related to

Sort By:
Pageof 31
Bone Marrow Transplantation|November 9, 2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)M Mohty, M Attal, G Marit, et al.
Lancet (London, England)|May 3, 2000
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow TransplantationF Frassoni, M Labopin, R Powles, et al.
Leukemia|January 20, 2009
Fully functional NK cells after unrelated cord blood transplantationV Beziat, S Nguyen, S Lapusan, et al.
Leukemia & Lymphoma|March 23, 2002
Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remissionA Delannoy, B Cazin, X Thomas, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
British Journal of Haematology|June 1, 1997
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM)G Socié, J Y Cahn, J Carmelo, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|May 7, 2017
[Not-for-profit: A report from the fourth annual symposium of ethics held by the National Institute for Blood Transfusion (France)]J Ceccaldi, J-B Thibert, A Haddad, et al.
British Journal of Haematology|February 14, 2002
Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemiaA Pigneux, M L Tanguy, M Michallet, et al.
Blood|June 8, 2001
Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remissionD Blaise, D Maraninchi, M Michallet, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 1998
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow TransplantationY Belkacemi, M Labopin, J P Vernant, et al.
Pageof 31